5067 Multidrug efflux transporter AcrB transmembrane domain
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Homogeneous metal compounds | 2 | 7.7 | 0.26× | q = 9.2e-3 | |
| Hydrocarbons | 1 | 0.1 | 9.07× | not tested | |
| Lipids and lipid-like molecules | 15 | 1.8 | 8.54× | not tested | |
| Phenylpropanoids and polyketides | 2 | 0.3 | 6.09× | not tested | |
| Organic oxygen compounds | 4 | 3.1 | 1.27× | not tested | |
| Organoheterocyclic compounds | 3 | 2.4 | 1.24× | not tested | |
| Organic acids and derivatives | 1 | 2.4 | 0.41× | not tested | |
| Homogeneous non-metal compounds | 1 | 3.4 | 0.29× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB02703 | FUA | Fusidic acid | 14 |
| DB03279 | LMU | Dodecyl-Alpha-D-Maltoside | 8 |
| DB04540 | CLR | Cholesterol | 8 |
| DB00163 | VIV | Vitamin E | 4 |
| DB04332 | ETE | 2-{2-[2-2-(Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethanol | 4 |
| DB02686 | UMQ | Undecyl-Beta-D-Maltopyranoside | 3 |
| DB00144 | P5S | Phosphatidyl serine | 2 |
| DB00199 | ERY | Erythromycin | 2 |
| DB00973 | H56 | Ezetimibe | 2 |
| DB02343 | P3G | 3,6,9,12,15-Pentaoxaheptadecane | 2 |
| DB06155 | AY6 | Rimonabant | 2 |
| DB00415 | AIC | Ampicillin | 1 |
| DB00537 | CPF | Ciprofloxacin | 1 |
| DB00601 | ZLD | Linezolid | 1 |
| DB00997 | DM2 | Doxorubicin | 1 |
| DB02810 | MHA | N-(2-Acetamido)Iminodiacetic Acid | 1 |
| DB03825 | RHQ | Rhodamine 6G | 1 |
| DB04705 | HC3 | 25-Hydroxycholesterol | 1 |
| DB17031 | ET | Homidium | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| PTY | PHOSPHATIDYLETHANOLAMINE | 151 |
| D12 | DODECANE | 79 |
| D10 | DECANE | 68 |
| HEX | HEXANE | 46 |
| OCT | N-OCTANE | 43 |
| C14 | TETRADECANE | 36 |
| CLR | CHOLESTEROL | 26 |
| DDR | (2S)-3-hydroxypropane-1,2-diyl didecanoate | 24 |
| 3PE | 1,2-Distearoyl-sn-glycerophosphoethanolamine | 20 |
| NImetal | NICKEL (II) ION | 20 |
| LPX | (2S)-3-{[(R)-(2-aminoethoxy)(hydroxy)phosphoryl]oxy}-2-hydroxypropyl hexadecanoate | 18 |
| FUA | FUSIDIC ACID | 13 |
| L6T | alpha-D-glucopyranosyl 6-O-dodecyl-alpha-D-glucopyranoside | 11 |
| Y01 | CHOLESTEROL HEMISUCCINATE | 10 |
| R16 | HEXADECANE | 9 |
| LMU | DODECYL-ALPHA-D-MALTOSIDE | 8 |
| XE9 | [3-(3-chloranyl-2-piperazin-1-yl-quinolin-6-yl)phenyl]methanamine | 8 |
| DD9 | nonane | 7 |
| 8K6 | Octadecane | 6 |
| OLC | (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate | 6 |